Howard Harrison, MD
Endocrinology, Diabetes & Metabolism · Virginia Beach, VANPI 1700850310
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,682 of the $19,561 with a category attached, or 64.8%. Novo Nordisk accounts for 68.3% of it on its own, with 45 other manufacturers making up the rest. Reporting peaked in 2019 at $13,644 and has fallen 92.4% since, to $1,035 in 2025. Among endocrinology, diabetes & metabolism clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 283 payments — averaging $69.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$13K
- Lilly USA, LLC$762
- Amgen$632
- Sanofi-aventis U.S. LLC$453
- Insulet Corporation$414
- Corcept Therapeutics$325
- plus $4K from 40 others
Across 15 payments — averaging $1806.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$27K
What the payments were for
- Speaking & faculty fees$12,68265%
- Travel & lodging$380%
- Food & beverage$6,63634%
- Education$860%
- Gifts$1191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tresiba$8,094
- Xultophy 100/3.6$2,325
- Ozempic$2,210
- iLet Bionic Pancreas$316
- MINIMED 780G$172
- TWIIST$160
- Prolia$125
- TZIELD$123
- AFREZZA$120
- Kerendia$120
- Tymlos$118
- JARDIANCE$113
- t:slim X2 insulin pump$112
- EVENITY$112
- DEXCOM G6 TRANSMITTER$107
- FARXIGA$102
- Korlym$102
How this compares
$19,561 in reported general payments places this provider in the 90th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 166 | $257,903 |
| TrulicityDulaglutide | 151 | $235,222 |
| MounjaroTirzepatide | 53 | $66,611 |
| FarxigaDapagliflozin Propanediol | 78 | $61,228 |
| TymlosAbaloparatide | 22 | $57,554 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 54 | $55,260 |
| RybelsusSemaglutide | 46 | $52,027 |
| ProglycemDiazoxide | 11 | $41,907 |
| JanuviaSitagliptin Phosphate | 29 | $40,650 |
| Humalog Kwikpen U-200Insulin Lispro | 14 | $40,436 |
| JardianceEmpagliflozin | 37 | $36,304 |
| AfrezzaInsulin Regular, Human | 19 | $29,126 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 48 | $27,653 |
| Humalog Kwikpen U-100Insulin Lispro | 59 | $22,951 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $22,801 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $762 | $324,453314 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $13,366 | $317,233242 claims |
| AstraZenecaFarxiga | $141 | $61,22878 claims |
| Radius Health, Inc.Tymlos | $212 | $57,55422 claims |
| MerckJanuvia | $48 | $40,65029 claims |
| Boehringer IngelheimJardiance | $320 | $36,30437 claims |
| Mannkind CorporationAfrezza | $292 | $29,12619 claims |
| AbbVieSynthroid | $212 | $9,287104 claims |
| Johnson & JohnsonXarelto | $13 | $8,69513 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $92 | $8,296678 claims |
| Sanofi-aventis U.S. LLCLantus | $453 | $1,97719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Virginia Beach
- Ana Marie DizonVirginia Beach$10K
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Domenica RubinoArlington$608K
- Samamtha HudsonMidlothian$372K
- Elias SirajNorfolk$316K
- Allen BurrisPowhatan$261K
- Samim EnayatFairfax$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.